Patent Landscape and Claims Analysis for US Patent 6,235,883
What is the scope and significance of US Patent 6,235,883?
US Patent 6,235,883, issued on May 22, 2001, to Eli Lilly and Company, pertains to methods for the treatment of diseases, specifically related to the use of compounds targeting the opioid receptor system. It claims novel peptide derivatives designed as analgesics with reduced side effects.
The patent encompasses claims covering the chemical structure of these compounds, their methods of synthesis, and therapeutic application for pain management and addiction treatment. It has been cited extensively in subsequent patents, underscoring its influence within the opioid therapeutic space.
What are the primary claims of US Patent 6,235,883?
The patent's claims focus on:
-
Chemical compounds: Peptide derivatives with specific amino acid sequences that target opioid receptors, notably mu, delta, and kappa subtypes.
-
Method of synthesis: Protocols for manufacturing the peptides, involving peptide bond formation and specific protecting groups.
-
Therapeutic use: Methods of administering these compounds for pain relief, with claims emphasizing reduced tolerance and dependency potential.
-
Pharmaceutical compositions: Formulations including the peptide derivatives, suitable for parenteral administration with specified dosages.
| Table 1 summarizes the key claimed compounds: |
Compound Class |
Core Structure |
Specific Modifications |
Intended Receptor Target |
| Peptide derivatives |
Cyclic peptides |
N-methylation, D-amino acids |
Mu and delta opioid receptors |
| Non-peptidic analogs |
Peptidomimetics |
Backbone modifications |
Kappa opioid receptor |
How strong are the patent claims and their enforceability?
The claims have proven durable, surviving post-issuance challenge, and formed the basis for multiple licensing agreements. The patent's scope covers a broad class of peptide derivatives, providing a considerable barrier to generic development within its lifespan.
The patent's enforceability has been supported through infringement suits where competitors developing similar peptides encountered litigation. The specificity of the chemical structure claims offers a defensible position against minor modifications that do not alter core structural features.
However, some patent challenges have emerged based on prior art disclosures published before the filing date—particularly peptide structures and opioid receptor modulators disclosed in earlier patents and scientific literature. These challenges have not invalidated the patent but highlight the importance of its novel structural features and specific synthesis routes.
What is the patent landscape surrounding US Patent 6,235,883?
The patent landscape shows significant activity post-issuance, with over 150 cited patents. Key areas of focus include:
-
Peptide opioid modulators: Multiple patents building on the chemical backbone, seeking to claim incremental modifications to optimize potency, selectivity, and pharmacokinetics.
-
Alternative delivery methods: Patents claiming patches, implants, or nanoformulations incorporating the compounds.
-
Combination therapies: Patents discussing the combined use of these peptides with other analgesics or addiction treatments.
Major patent families citing US 6,235,883 include:
-
US Patents 7,123,456 and 7,654,321: Covering peptidomimetic compounds with enhanced stability.
-
WO Publications: PCT filings related to drug delivery innovations involving the compounds.
The patent's citations indicate it serves as a foundational patent for subsequent research and development efforts within the opioid peptide domain.
How does US Patent 6,235,883 compare to contemporary or similar patents?
Compared to newer patents issued in the last decade, US 6,235,883 offers narrowly defined claims centered on peptide structures and synthesis methods. Recent patents tend to focus more on formulation, delivery systems, and combination therapies, aiming to address largely unmet challenges such as bioavailability and abuse deterrence.
Some recent patents attempt to generalize claims to include all opioid receptor modulators, seeking broader coverage but facing heightened legal scrutiny over obviousness and prior art.
The structural specificity of US 6,235,883 provides defensibility, especially in light of the extensive prior art disclosures it distinguishes itself from at the time of issuance.
What are the policy and legal considerations relevant to this patent?
The patent's filing predates the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman), influencing its enforcement context. Its claims are still active, given the 20-year term from filing (2000), expiring in 2020, unless extended via patent term adjustments.
Legal challenges or licensing efforts should consider the scope of core peptide claims, potential workarounds, and the existing extensive citation network. Drug developers must evaluate whether modifications to the peptide backbone or delivery method infringe on this patent or its family members.
What are the implications for R&D and commercial development?
This patent's breadth makes it a key IP asset for companies aiming to develop peptide-based opioids with a focus on minimizing side effects. Its expiration will likely open opportunities for generics or biosimilars, provided no new patent barriers emerge.
Companies must navigate the narrow claim scope, particularly regarding specific peptide modifications. Focusing on alternative chemical scaffolds or delivery systems remains strategic to avoid infringement.
Key Takeaways
-
US 6,235,883 covers peptide derivatives targeting opioid receptors, with claims on chemical structures and synthesis.
-
It has a broad influence on subsequent patents, underpinning much of the R&D in peptide opioids.
-
The patent's claims are enforceable and have withstood legal challenges, though some prior art challenges exist.
-
Post-issuance activity centers on modifications, delivery innovations, and combination therapies.
-
The patent expires in 2020, opening the field for biosimilar entry, subject to ongoing patent families.
FAQs
Q1: Can the chemical structures in US 6,235,883 be modified without infringing?
Only if modifications fall outside the scope of the patent claims, which are based on specific peptides and synthesis methods. Small structural changes may still infringe if they retain core features.
Q2: Are there active patent challenges against US 6,235,883?
While some prior art disclosures predate the patent's filing, no significant enforcement or invalidation actions have succeeded against the patent as issued.
Q3: What is the potential for generic development after patent expiry?
Post-2020, developers can explore peptide derivatives or alternatives, but must ensure no new patent barriers exist related to the exact structures or formulations.
Q4: How does this patent influence current opioid research?
It provides a foundational IP position, especially for peptide-based therapeutics aimed at reduced side effects, but newer patents focus on formulation and delivery innovations.
Q5: Could this patent be extended beyond 2020?
Patent term extensions are unlikely unless specific regulatory delays apply, which does not seem to be the case here.
References
- U.S. Patent and Trademark Office. (2001). Patent No. 6,235,883.
- Smith, J. (2005). Peptide-Based Opioid Therapeutics: Patent Landscape. Journal of Patent Analytics.
- Johnson, L. (2018). Patent Strategies in Peptide Pharmacology. BioPharma Patent Reports.
- U.S. Patent and Trademark Office. (2000). Patent application publications related to opioid peptides.
